Navigation

Pancreatic cancer - capectitabine [ID389]

Status: Suspended
Expected date of issue: TBC
Referral date: December 2007
Process: STA
Topic area:
  • Cancer
  • Digestive system
 

NICE project team

Executive Lead: Andrew Dillon
Technical Lead: Andres Roman
Communications manager: Alice Law
Project manager: TBC
Assessment Group / Evidence Review Group: TBC
Top


 

Provisional schedule

Closing date for invited submissions / evidence submission: TBC
1st appraisal committee meeting: TBC
2nd appraisal committee meeting TBC
Top


 

Consultees and commentators

To be confirmed

Top


 

Project history

Date Update
26 June 2009

The manufacturer of capecitabine has advised us that they have not applied for regulatory approval in relation to this product at this time. The Institute has therefore decided to remove this appraisal from its current work programme.

As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.

Top


 

Key documents

This page was last updated: 28 February 2012

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.